ChemicalBook
Chinese english Germany Korea

5,5-ジフェニルヒダントイン

5,5-ジフェニルヒダントイン 化学構造式
57-41-0
CAS番号.
57-41-0
化学名:
5,5-ジフェニルヒダントイン
别名:
5,5-ジフェニルヒダントイン;デニル;ソダントン;エプタル;1,5-ジヒドロ-5,5-ジフェニル-2H-イミダゾール-2,4(3H)-ジオン;ジフェントイン;ジラビッド;ジ-ヒダン;ヒダンタール;4,4-ジフェニル-2,3,4,5-テトラヒドロ-1H-イミダゾール-2,5-ジオン;ヒダントール;5,5-ジフェニル-イミダゾリジン-2,4-ジオン;5,5-ジフェニルイミダゾリジン-2,4-ジオン;ジフェニルヒダントイン;ジフェニルヒドラントイン;ジ-ラン;レピトイン;ジヒコン;アレビアチン;ゼントロピル
英語化学名:
5,5-Diphenylhydantoin
英語别名:
Ekko;LATH;base;Eptal;Hidan;Denyl;Convul;Danten;Epamin;Epised
CBNumber:
CB3139264
化学式:
C15H12N2O2
分子量:
252.27
MOL File:
57-41-0.mol

5,5-ジフェニルヒダントイン 物理性質

融点 :
293-295 °C(lit.)
沸点 :
395.45°C (rough estimate)
比重(密度) :
1.1562 (rough estimate)
屈折率 :
1.5906 (estimate)
闪点 :
11 °C
貯蔵温度 :
2-8°C
溶解性:
DMSO: soluble
酸解離定数(Pka):
pKa 8.43(H2O,t =25,I=0.025) (Uncertain)
Density:
1.26 g/cm3
Melting Point:
286 °C
外見 :
Powder
色:
White to almost white
水溶解度 :
<0.01 g/100 mL at 19 ºC
Merck :
14,7322
BRN :
384532
安定性::
Stable. Combustible. Incompatible with strong oxidizing agents, strong bases.
InChIKey:
CXOFVDLJLONNDW-UHFFFAOYSA-N
CAS データベース:
57-41-0(CAS DataBase Reference)
NISTの化学物質情報:
5,5-Diphenylhydantoin(57-41-0)
EPAの化学物質情報:
2,4-Imidazolidinedione, 5,5-diphenyl-(57-41-0)
安全性情報
  • リスクと安全性に関する声明
  • 危険有害性情報のコード(GHS)
主な危険性  T,Xn,F
Rフレーズ  45-61-22-63-40-39/23/24/25-23/24/25-11-20/21/22
Sフレーズ  53-45-36/37-16-7
RIDADR  2811
WGK Germany  3
RTECS 番号 MU1050000
自然発火温度 550 °C
国連危険物分類  6.1(b)
容器等級  II
HSコード  29332100
有毒物質データの 57-41-0(Hazardous Substances Data)
毒性 LD50 in mice (mg/kg): 92 i.v.; 110 s.c. (Stille, Brunckow)
化審法 (9)-621
絵表示(GHS)
注意喚起語 Danger
危険有害性情報
コード 危険有害性情報 危険有害性クラス 区分 注意喚起語 シンボル P コード
H225 引火性の高い液体および蒸気 引火性液体 2 危険 P210,P233, P240, P241, P242, P243,P280, P303+ P361+P353, P370+P378,P403+P235, P501
H302 飲み込むと有害 急性毒性、経口 4 警告 P264, P270, P301+P312, P330, P501
H303 飲み込むと有害のおそれ 急性毒性、経口 5 P312
H317 アレルギー性皮膚反応を起こすおそれ 感作性、皮膚 1 警告 P261, P272, P280, P302+P352,P333+P313, P321, P363, P501
H340 遺伝性疾患のおそれ 生殖細胞変異原性 1A, 1B 危険
H350 発がんのおそれ 発がん性 1A, 1B 危険
H351 発がんのおそれの疑い 発がん性 2 警告 P201, P202, P281, P308+P313, P405,P501
H360 生殖能または胎児への悪影響のおそれ 生殖毒性 1A, 1B 危険
H370 臓器の障害 特定標的臓器有害性、単回暴露 1 危険 P260, P264, P270, P307+P311, P321,P405, P501
H372 長期にわたる、または反復暴露により臓器の障 害 特定標的臓器有害性、単回暴露 1 危険 P260, P264, P270, P314, P501
注意書き
P201 使用前に取扱説明書を入手すること。
P202 全ての安全注意を読み理解するまで取り扱わないこ と。
P210 熱/火花/裸火/高温のもののような着火源から遠ざ けること。-禁煙。
P260 粉じん/煙/ガス/ミスト/蒸気/スプレーを吸入しないこ と。
P261 粉じん/煙/ガス/ミスト/蒸気/スプレーの吸入を避ける こと。
P264 取扱い後は皮膚をよく洗うこと。
P264 取扱い後は手や顔をよく洗うこと。
P270 この製品を使用する時に、飲食または喫煙をしないこ と。
P280 保護手袋/保護衣/保護眼鏡/保護面を着用するこ と。
P301+P310 飲み込んだ場合:直ちに医師に連絡すること。
P307+P311 暴露した場合:医師に連絡すること。
P308+P313 暴露または暴露の懸念がある場合:医師の診断/手当てを 受けること。
P311 医師に連絡すること。
P405 施錠して保管すること。
P501 内容物/容器を...に廃棄すること。

5,5-ジフェニルヒダントイン 価格 もっと(17)

メーカー 製品番号 製品説明 CAS番号 包装 価格 更新時間 購入
富士フイルム和光純薬株式会社(wako) W01TRCD491650 5,5-ジフェニルヒダントイン
5,5-Diphenyl Hydantoin
57-41-0 1g ¥11300 2018-12-26 購入
富士フイルム和光純薬株式会社(wako) W01TRCD491650 5,5-ジフェニルヒダントイン
5,5-Diphenyl Hydantoin
57-41-0 10g ¥18800 2018-12-26 購入
東京化成工業 D0894 5,5-ジフェニルヒダントイン >99.0%(T)
5,5-Diphenylhydantoin >99.0%(T)
57-41-0 25g ¥2300 2018-12-04 購入
関東化学株式会社(KANTO) 17173-2A 5,5‐ジフェニルヒダントイン
5,5‐Diphenylhydantoin
57-41-0 5g ¥3900 2018-12-13 購入
関東化学株式会社(KANTO) 10446-30 5,5‐ジフェニルヒダントイン >98.0%(T)
5,5‐Diphenylhydantoin >98.0%(T)
57-41-0 25g ¥4500 2018-12-13 購入

5,5-ジフェニルヒダントイン MSDS


5,5-Diphenyl-2,4-imidazolidinedione

5,5-ジフェニルヒダントイン 化学特性,用途語,生産方法

外観

白色の粉末

溶解性

水 <0.01 g/100 mL at 19℃。エタノール,水酸化ナトリウム溶液に可溶、クロロホルムに微溶、水に不溶。

用途

薬理研究用。

用途

水酸化ナトリウム溶液 [用途(作用)]ナトリウム透過性抑制作用を 示します。

用途

ナトリウム透過性抑制作用を 示します。

効能

抗てんかん薬

商品名

アレビアチン (大日本住友製薬); アレビアチン (大日本住友製薬); ヒダントール (藤永製薬); ヒダントール (藤永製薬)

化学的特性

white crystals or powder

化学的特性

Phenytoin is a crystalline compound

使用

Reduces incidence of grand mal seizures; appears to stabilize excitable membranes perhaps through effects on Na+, K+, and Ca2+ channels.

使用

A sodium channel protein inhibitor

定義

ChEBI: A imidazolidine-2,4-dione that consists of hydantoin bearing two phenyl substituents at position 5.

brand name

Anticonvulsant. Dilantin (Pfizer) [Name previously used: Diphenylhydantoin.].

生物学の機能

Phenytoin is a valuable agent for the treatment of generalized tonic–clonic seizures and for the treatment of partial seizures with complex symptoms. The establishment of phenytoin (at that time known as diphenylhydantoin) in 1938 as an effective treatment for epilepsy was more than simply the introduction of another drug for treatment of seizure disorders. Until that time the only drugs that had any beneficial effects in epilepsy were the bromides and barbiturates, both classes of compounds having marked CNS depressant properties. The prevailing view among neurologists of that era was that epilepsy was the result of excessive electrical activity in the brain and it therefore seemed perfectly reasonable that CNS depressants would be effective in antagonizing the seizures. Consequently,many patients received high doses of barbiturates and spent much of their time sedated. Also, since CNS depression was considered to be the mechanism of action of AEDs, the pharmaceutical firms were evaluating only compounds with profound CNS depressant properties as potential antiepileptic agents. It was, therefore, revolutionary when phenytoin was shown to be as effective as phenobarbital in the treatment of epilepsy without any significant CNS depressant activity. This revolutionized the search for new anticonvulsant drugs as well as immediately improving the day-to-day functioning of epileptic patients.
An understanding of absorption, binding, metabolism, and excretion is more important for phenytoin than it is for most drugs. Following oral administration, phenytoin absorption is slow but usually complete, and it occurs primarily in the duodenum. Phenytoin is highly bound (about 90%) to plasma proteins, primarily plasma albumin. Since several other substances can also bind to albumin, phenytoin administration can displace (and be displaced by) such agents as thyroxine, triiodothyronine, valproic acid, sulfafurazole, and salicylic acid.

一般的な説明

Fine white or almost white crystalline powder. Odorless or almost odorless. Tasteless.

空気と水の反応

Insoluble in water.

反応プロフィール

5,5-Diphenylhydantoin is an amide. Amides/imides react with azo and diazo compounds to generate toxic gases. Flammable gases are formed by the reaction of organic amides/imides with strong reducing agents. Amides are very weak bases (weaker than water). Imides are less basic yet and in fact react with strong bases to form salts. That is, they can react as acids. Mixing amides with dehydrating agents such as P2O5 or SOCl2 generates the corresponding nitrile. The combustion of these compounds generates mixed oxides of nitrogen (NOx). 5,5-Diphenylhydantoin is incompatible with strong oxidizers and strong bases.

火災危険

Flash point data for 5,5-Diphenylhydantoin are not available; however, 5,5-Diphenylhydantoin is probably combustible.

臨床応用

Phenytoin (Dilantin) was originally introduced for the control of convulsive disorders but has now also been shown to be effective in the treatment of cardiac arrhythmias. Phenytoin appears to be particularly effective in treating ventricular arrhythmias in children.
Phenytoin, like lidocaine, is more effective in the treatment of ventricular than supraventricular arrhythmias. It is particularly effective in treating ventricular arrhythmias associated with digitalis toxicity, acute myocardial infarction, open-heart surgery, anesthesia, cardiac catheterization, cardioversion, and angiographic studies.
Phenytoin finds its most effective use in the treatment of supraventricular and ventricular arrhythmias associated with digitalis intoxication. The ability of phenytoin to improve digitalis-induced depression of A-V conduction is a special feature that contrasts with the actions of other antiarrhythmic agents.

臨床応用

Phenytoin is one of very few drugs that displays zero-order (or saturation) kinetics in its metabolism.At low blood levels the rate of phenytoin metabolism is proportional to the drug’s blood 1evels (i.e., first-order kinetics). However, at the higher blood levels usually required to control seizures, the maximum capacity of drug-metabolizing enzymes is often exceeded (i.e., the enzyme is saturated), and further increases in the dose of phenytoin may lead to a disproportionate increase in the drug’s blood concentration. Since the plasma levels continue to increase in such a situation, steady-state levels are not attained, and toxicity may ensue. Calculation of half-life (t1/2) values for phenytoin often is meaningless, since the apparent half-life varies with the drug blood level.
Acute adverse effects seen after phenytoin administration usually result from overdosage. They are generally characterized by nystagmus, ataxia, vertigo, and diplopia (cerebellovestibular dysfunction). Higher doses lead to altered levels of consciousness and cognitive changes.
A variety of idiosyncratic reactions may be seen shortly after therapy has begun. Skin rashes, usually morbilliform in character, are most common. Exfoliative dermatitis or toxic epidermal necrolysis (Lyellís syndrome) has been observed but is infrequent. Other rashes occasionally have been reported, as have a variety of blood dyscrasias and hepatic necrosis.

副作用

The most common side effect in children receiving long-term therapy is gingival hyperplasia, or overgrowth of the gums (occurs in up to 50% of patients). Although the condition is not serious, it is a cosmetic problem and can be very embarrassing to the patient. Hirsutism also is an annoying side effect of phenytoin, particularly in young females. Thickening of subcutaneous tissue, coarsening of facial features, and enlargement of lips and nose (hydantoin facies) are often seen in patients receiving long-term phenytoin therapy. Peripheral neuropathy and chronic cerebellar degeneration have been reported, but they are rare.
There is evidence that phenytoin is teratogenic in humans, but the mechanism is not clear. However, it is known that phenytoin can produce a folate deficiency, and folate deficiency is associated with teratogenesis. Only a few well-documented drug combinations with phenytoin may necessitate dosage adjustment. Coadministration of the following drugs can result in elevations of plasma phenytoin levels in most patients: cimetidine, chloramphenicol, disulfiram, sulthiame, and isoniazid (in slow acetylators). Phenytoin often causes a decline in plasma carbamazepine levels if these two drugs are given concomitantly.
Ethotoin and mephenytoin are congeners of phenytoin that are marketed as AEDs in the United States. They are not widely used.

副作用

The rapid IV administration of phenytoin can present a hazard. Respiratory arrest, arrhythmias, and hypotension have been reported.

安全性プロファイル

Confirmed carcinogen producing lymphoma, Hodgkin's disease, tumors of the skin and appendages. Experimental carcinogenic and tumorigenic data. A human poison by ingestion. Poison experimentally by ingestion, subcutaneous, intravenous, and intraperitoneal routes. Moderately toxic by an unspecified route. Experimental teratogenic and reproductive effects. Human systemic effects by ingestion: dermatitis, change in motor activity (specific assay), ataxia (loss of muscle coordmation), degenerative brain changes, encephalitis, hallucinations, dtstorted perceptions, irritabihty, and jaundice. Human teratogenic effects by ingestion: developmental abnormalities of the central nervous system, carlovascular (circulatory) system, musculoskeletal system, craniofacial area, skin and skin appendages, eye, ear, other developmental abnormalities. Effects on newborn include abnormal growth statistics (e.g., reduced weight gain), physical abnormakties, other postnatal measures or effects, and delayed effects. Human mutation data reported. A drug for the treatment of grand mal and psychomotor seizures. When heated to decomposition it emits toxic fumes of NOx

職業ばく露

Phenytoin is an amide pharmaceutical used in the treatment of grand mal epilepsy, Parkinson’s syndrome; and in veterinary medicine. Human exposure to phenytoin occurs principally during its use as a drug. Figures on the number of patients using phenytoin are not available, but phenytoin is given to a major segment of those individuals with epilepsy. The oral dose rate is initially 100 mg given 3 times per day and can gradually increase by 100 mg every 24 weeks until the desired therapeutic response is obtained. The intravenous dose is 200350 mg/day.

薬物相互作用

Plasma phenytoin concentrations are increased in the presence of chloramphenicol, disulfiram, and isoniazid, since the latter drugs inhibit the hepatic metabolism of phenytoin. A reduction in phenytoin dose can alleviate the consequences of these drug–drug interactions.

Carcinogenicity

Phenytoin and its sodium salt are reasonably anticipated to be human carcinogens based on sufficient evidence from studies in experimental animals.

輸送方法

UN2811 Toxic solids, organic, n.o.s., Hazard Class: 6.1; Labels: 6.1-Poisonous materials, Technical Name Required. UN3249 Medicine, solid, toxic, n.o.s., Hazard Class: 6.1; Labels: 6.1-Poisonous materials.

純化方法

Crystallise the hydantoin from EtOH. [Beilstein 24 III/IV 1748.]

不和合性

Incompatible with oxidizers (chlorates, nitrates, peroxides, permanganates, perchlorates, chlorine, bromine, fluorine, etc.); contact may cause fires or explosions. Keep away from alkaline materials, strong bases, strong acids, oxoacids, epoxides. Similar organic amides react with azo and diazo compounds, releasing toxic gases. Contact with reducing agents can release flammable gases. Amides are very weak bases but they can react as acids, forming salts. Mixing amides with dehydrating agents such as phosphorus pentoxide or thionyl chloride generates the corresponding nitrile.

予防処置

Phenytoin either should not be used or should be used cautiously in patients with hypotension, severe bradycardia, high-grade A-V block, severe heart failure, or hypersensitivity to the drug.
Because of the increase in A-V transmission observed with phenytoin administration, it should not be given to patients with atrial flutter or atrial fibrillation. Phenytoin will probably not restore normal sinus rhythm and may dangerously accelerate the ventricular rate.

法令条例

Consumer Product Safety Commission (CPSC)
Any orally administered prescription drug for human use requires child-resistant packaging.
Environmental Protection Agency (EPA)
Emergency Planning and Community Right-To-Know Act
Toxics Release Inventory: Listed substance subject to reporting requirements.
Food and Drug Administration (FDA)
Phenytoin is a prescription drug subject to labeling and other requirements.

5,5-ジフェニルヒダントイン 上流と下流の製品情報

原材料

準備製品


5,5-ジフェニルヒダントイン 生産企業

Global( 173)Suppliers
名前 電話番号 ファックス番号 電子メール 国籍 製品カタログ 優位度
Henan DaKen Chemical CO.,LTD.
+86-371-55531817
info@dakenchem.com CHINA 21676 58
Henan Tianfu Chemical Co.,Ltd.
0371-55170693
0371-55170693 info@tianfuchem.com CHINA 20672 55
Mainchem Co., Ltd.
+86-0592-6210733
+86-0592-6210733 sales@mainchem.com CHINA 32447 55
PI & PI BIOTECH INC.
020-81716320
020-81716319 Sales@pipitech.com CHINA 2543 55
Wuhan FengyaoTonghui Chemical Products Co., Ltd. 027-87466205 15377573527
027-87466205 2678564200@qq.com China 19024 58
J & K SCIENTIFIC LTD. 400-666-7788 +86-10-82848833
86-10-82849933 jkinfo@jkchemical.com;market6@jkchemical.com China 96815 76
Meryer (Shanghai) Chemical Technology Co., Ltd. +86-(0)21-61259100(Shanghai) +86-(0)755-86170099(ShenZhen) +86-(0)10-62670440(Beijing)
+86-(0)21-61259102(Shanghai) +86-(0)755-86170066(ShenZhen) +86-(0)10-88580358(Beijing) sh@meryer.com China 40269 62
Alfa Aesar 400-610-6006; 021-67582000
021-67582001/03/05 saleschina@alfa-asia.com China 30163 84
TCI (Shanghai) Development Co., Ltd. 021-67121386 / 800-988-0390
021-67121385 Sales-CN@TCIchemicals.com China 24555 81
Energy Chemical 021-58432009 / 400-005-6266
021-58436166-800 info@energy-chemical.com China 44025 61

57-41-0(5,5-ジフェニルヒダントイン)キーワード:


  • 57-41-0
  • NCI-H2106[H2106] Cell
  • PHENYTOIN BASE
  • PHENYTION
  • PHENYTOIN
  • 5,5-DIPHENYLHYDANTHOIN
  • 5,5-DIPHENYLHYDANTOIN
  • 5,5-DIPHENYL-2,4-IMIDAZOLIDINEDIONE
  • DIPHENYLHYDANTOIN
  • LABOTEST-BB LT00159593
  • 2,4-Imidazolidinedione, 5,5-diphenyl-
  • 5,5-diphenyl-hydantoi
  • 5,5-Diphenylimidazolidin-2,4-dione
  • 5,5-Dwufenylohydantoina
  • Aleviatin
  • Antisacer
  • Causoin
  • Citrullamon
  • Citrulliamon
  • Comital
  • Comitoina
  • component of Mebroin
  • Convul
  • Danten
  • Elepsindon
  • Enkelfel
  • Epamin
  • Epasmir 5
  • Epdantoine simple
  • epdantoinesimple
  • Epifenyl
  • 5,5-ジフェニルヒダントイン
  • デニル
  • ソダントン
  • エプタル
  • 1,5-ジヒドロ-5,5-ジフェニル-2H-イミダゾール-2,4(3H)-ジオン
  • ジフェントイン
  • ジラビッド
  • ジ-ヒダン
  • ヒダンタール
  • 4,4-ジフェニル-2,3,4,5-テトラヒドロ-1H-イミダゾール-2,5-ジオン
  • ヒダントール
  • 5,5-ジフェニル-イミダゾリジン-2,4-ジオン
  • 5,5-ジフェニルイミダゾリジン-2,4-ジオン
  • ジフェニルヒダントイン
  • ジフェニルヒドラントイン
  • ジ-ラン
  • レピトイン
  • ジヒコン
  • アレビアチン
  • ゼントロピル
  • 5,5-ジフェニル-2,4-イミダゾリジンジオン
  • フェニトイン
  • 5,5-ジフェニル-2,4-イミダゾリジンジオン[別名:フェニトイン]
  • 5,5‐ジフェニルヒダントイン
  • フェニトイン 溶液
  • フェニトイン (JP17)
  • 抗痙攣薬
Copyright 2017 © ChemicalBook. All rights reserved